Genmab — November 2018

[E_L]

on ASCENT trial https://www.myeloma.org/blog/dr-duries/ascent-trial-treat-high-risk-smoldering-multiple-myeloma-launching-across-us https://clinicaltrials.gov/ct2/show/NCT03289299?term=daratumumab+ascent&rank=1

[Nickstar]

den lægger bare an til at bryde 1000 en af dagene er jeg sikker på

[E_L]

J&J adds to lung cancer arsenal with Yuhan deal https://www.biocentury.com/bc-extra/company-news/2018-11-05/jj-adds-lung-cancer-arsenal-yuhan-deal "giving JNJ….its second compound against EGFR"

[E_L]

J&J's other EGFR inhibitor is JNJ-61186372. Janssen is evaluating that product, a bispecific antibody targeting EGFR and c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene), in Phase I testing for NSCLC.

[E_L]

Yuhan told BioCentury that it and Janssen will begin next year [a global Phase III monotherapy trial of lazertinib] and a global Phase Ib combination trial of lazertinib plus JNJ-61186372.

[Schiff]

Zacks Equity Research?? https://finance.yahoo.com/news/genmab-gnmsf-earnings-expected-grow-153003579.html

[bibob]

DDB om aktierne efter midvejdvalget. https://danskebank.dk/privat/news/investeringsnyt/forside---investeringsnyt/chefstrateg---saadan-kan-trumps-valglussing-ramme-dine-aktier

[JKY_VH]

Nordea skriver stort set det samme og anbefaler overvægt af aktier. De forventer, at aktier stille og roligt vil kravle opad fra nu, og om 12 måneder vil have givet et afkast på globale aktier på 10-15 pct.

[bibob]

Håber de får ret JKY :-). Det er sundheds aktier der trækker op over det hele.

[Helge_LarsenPI-redaktør]

Hans-Henrik om Midtvejsvalget: http://www.proinvestor.com/debat/76466

[JKY_VH]

Ja bibob, det kan vi da håbe, og så må Novod godt genvinde tilliden til JvW og Genmab.

[GeorgeBest]

Trump i en nøddeskal https://twitter.com/aljwhite/status/1060224698561318913?s=21

[Nickstar]

Er glad for du har fået HH ind i folden, Helge.

[Helge_LarsenPI-redaktør]

Vi har arbejdet sammen før. Nu fik vi muligheden igen.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[polle1]

God morgen og god dag

[E_L]

NEJM : Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation https://www.nejm.org/doi/full/10.1056/NEJMoa1807438

[E_L]

"Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions." ………..wtf

[E_L]

New trial: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) https://clinicaltrials.gov/ct2/show/NCT03734198